Sunitinib

From Anvita Health Wiki

Contents 1 Indications 2 Dosage 3 Adverse-effects 4 Drug-interactions 5 Mechanism-of-action 6 More General Terms 7 References

Indications

• treatment of renal cell carcinoma
• treatment of imatinib-resistant gastrointestinal stromal tumor

Dosage

• 50 mg PO QD for 4 weeks followed by 2 week drug holiday
  

• Capsules: 12.5 mg, 25 mg or 50 mg

Adverse-effects

• cardiovascular events
• skin & tissue problems
• gastrointestinal events
• hemorrhage
• hypertension
• hematological problems
• venous thromboembolism

• pulmonary embolism

• hypothyroidism

Drug-interactions

• several reports of microangiopathic hemolytic anemia in patients with solid tumors receiving Avastin in combination with sunitinib malate; this combination is not recommended [2]

Mechanism-of-action

• tyrosine kinase inhibitor

More General Terms

• monoclonal antibody
• tyrosine kinase inhibitor
• antineoplastic agent (chemotherapeutic agent)

References

1. Prescriber's Letter 14(2): 2007 New drugs approved by the FDA in 2006 Detail-Document#: [1] (subscription needed) [2]
2. FDA Medwatch [3]
3. Sutent [4]
4. National Cancer Institute: Sunitinib Malate [5]
   - Wikipedia: Sunitinib [6]
5. RxList Sutent [7]
6. National Guideline Clearinghouse
   - Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. National Institute for Health and Clinical Excellence (NICE) ngc-guideline: [8]
   - Sunitinib for the treatment of gastrointestinal stromal tumours. National Institute for Health and Clinical Excellence (NICE) ngc-guideline: [9]

sunitinib (Sutent)